Plasticell, a biotechnology company using combinatorial cell-culture technologies for optimization of cell and gene therapy manufacturing, has formed a collaboration agreement with Sphere Fluidics, a company specializing in single-cell encapsulation and screening.

Plasticell has used its proprietary Combinatorial Cell Culture (CombiCult) platform to develop gene transduction protocols as alternatives to commercial transfection reagents currently used in gene-therapy trials. Sphere Fluidics has developed high-throughput single-cell manipulation and screening technology in picoliter volumes. The two partners aim to combine their technologies to develop quantitatively accurate gene transduction systems with improved efficiency, safety, and cost savings.

Source: Plasticell